Stereotactic Drainage Treatment is Associated with Improved Long-Term Neurological Recovery in Small-to-Moderate Volume Basal Ganglia Hemorrhages: A Systematic Review and Meta-Analysis.
Jiepu Wang, Xiongjie Fu, Zihao An et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis compared stereotactic drainage treatment (SDT) with conservative medical treatment (CMT) for spontaneous basal ganglia intracerebral hemorrhage of ≤ 50 mL. Eleven studies involving 1634 participants were analyzed. SDT was associated with a higher proportion of favorable functional outcomes (modified Rankin Scale score 0-2) up to 12 months, with benefits reported in both hematoma-volume strata and significant superiority from 3 months onwards (all P < 0.001). Mortality did not differ significantly. SDT was also associated with faster hematoma resolution and shorter hospital stay, without significant differences in infection or rebleeding.
Key findings
- Across 11 studies and 1634 participants, SDT was associated with more favorable functional outcomes up to 12 months (P < 0.001).
- Functional benefits were reported for both cohort-mean hematoma-volume strata (< 25 mL and 25-50 mL), with superiority from 3 months onwards (all P < 0.001).
- Mortality did not differ significantly between SDT and CMT groups (P = 0.05).
- SDT was associated with faster hematoma resolution and shorter hospital stay (all P < 0.05), without significant differences in infection (P = 0.17) or rebleeding (P = 0.19).
Why it matters
Management of small-to-moderate basal ganglia hemorrhage remains controversial. These pooled findings suggest that stereotactic drainage may be associated with better functional recovery and more rapid hematoma resolution, while measured safety outcomes were not significantly different. The results may inform discussion of treatment options, but the evidence does not establish a causal benefit or resolve which patients are most likely to benefit.
What to keep in mind
The analysis pooled 11 studies, and the abstract does not identify them as randomized trials. The authors call for large, multicenter randomized trials with standardized protocols to confirm efficacy and safety and refine patient selection.